In:
Cancer, Wiley, Vol. 95, No. 2 ( 2002-07-15), p. 340-353
Abstract:
Gemcitabine in combination with vinorelbine is an effective therapy for advanced non small cell lung carcinoma in both the first and second line setting as shown in the current Phase II trial. The toxicity profile is favorable with minimal neurotoxicity and alopecia, though there was a large percentage of missed doses when the drug was given on a three out of week week schedule. Prospects for the combination of this well‐tolerated regimen with biologic therapy are discussed.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2002
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1